AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min snip
Why One Drug Company Held Back a Better Drug
The Daily
Legal and Ethical Concerns in Pharmaceutical Competition
The strategies discussed here may not be about creating new treatments, but rather about using legal and financial power to block competition. In the case of Gilead and Tanafovir, this resulted in the delay of a potentially less harmful drug. There are both legal and ethical concerns surrounding this issue, particularly because patients' health was affected. The courts will determine whether these lawsuits can proceed based on whether Gilead knew the newer drug would be better. The key question is how much evidence was necessary for Gilead to have a responsibility to advance the drug.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode